Functional Precision Oncology Filling The Gap Left By Genomics Based Glioblastoma remains the most malignant and intrinsically resistant brain tumour in adults. precision oncology refers to the evaluation of treatment efficacies and vulnerabilities of (ex vivo) living tumor cells in a highly personalized way. In this review, we discuss the current state of the art of transforming technologies, tools and challenges for functional precision oncology and how these could improve therapy selection for gbm patients.
Cancers An Open Access Journal From Mdpi This study represents significant progress toward the broader application of functional precision medicine in neuro oncology. it demonstrates the feasibility of rapid, ex vivo drug testing platforms that work directly with acute patient samples, avoiding the need for time consuming cultivation. Here this review examines both historical and contemporary treatment strategies for high grade gliomas and explores underlying reasons for the limited success of multiple precision oncology. The platform is concurrently being validated in other high unmet need indications, including early stage breast cancer (nct05435352) and metastatic kidney cancer (nct06264479), aiming to advance precision treatment selection and transform clinical oncology. Review overcoming chemoresistance in glioblastoma: mechanisms, therapeutic strategies, and functional precision medicine maria y. kordyukova 1, * , timofey k. bulgakov 1,2 , maria a. sorokina 1,3.
Molecular Oncology Cancer Glioblastoma Tumor International The platform is concurrently being validated in other high unmet need indications, including early stage breast cancer (nct05435352) and metastatic kidney cancer (nct06264479), aiming to advance precision treatment selection and transform clinical oncology. Review overcoming chemoresistance in glioblastoma: mechanisms, therapeutic strategies, and functional precision medicine maria y. kordyukova 1, * , timofey k. bulgakov 1,2 , maria a. sorokina 1,3. In this review, we discuss the current state of the art of transforming technologies, tools and challenges for functional precision oncology and how these could improve therapy selection for gbm patients. Although these neuroimaging techniques have improved the precision of surgical interventions, they are limited in terms of addressing the molecular and genetic complexities underlying diseases, for example, glioblastomas, refractory epilepsy, or neurodegenerative disorders. This review summarizes the current status of precision oncology in glioblastoma (gbm), the most common and aggressive primary brain tumor in adults with a median survival below 2 years. With this review, we aimed to provide a comprehensive overview of the current literature on molecular biomarkers and precision therapeutic strategies in glioblastoma to condense the available information in one place and emphasize what is known and what needs to be further developed.
Diagnosis And Management Of Glioblastoma A Comprehensive Perspective In this review, we discuss the current state of the art of transforming technologies, tools and challenges for functional precision oncology and how these could improve therapy selection for gbm patients. Although these neuroimaging techniques have improved the precision of surgical interventions, they are limited in terms of addressing the molecular and genetic complexities underlying diseases, for example, glioblastomas, refractory epilepsy, or neurodegenerative disorders. This review summarizes the current status of precision oncology in glioblastoma (gbm), the most common and aggressive primary brain tumor in adults with a median survival below 2 years. With this review, we aimed to provide a comprehensive overview of the current literature on molecular biomarkers and precision therapeutic strategies in glioblastoma to condense the available information in one place and emphasize what is known and what needs to be further developed.
Diagnosis And Management Of Glioblastoma A Comprehensive Perspective This review summarizes the current status of precision oncology in glioblastoma (gbm), the most common and aggressive primary brain tumor in adults with a median survival below 2 years. With this review, we aimed to provide a comprehensive overview of the current literature on molecular biomarkers and precision therapeutic strategies in glioblastoma to condense the available information in one place and emphasize what is known and what needs to be further developed.